<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04621279</url>
  </required_header>
  <id_info>
    <org_study_id>v1.1</org_study_id>
    <nct_id>NCT04621279</nct_id>
  </id_info>
  <brief_title>Cool Prime Comparative Effectiveness Study for Mild HIE</brief_title>
  <acronym>COOLPRIME</acronym>
  <official_title>COOLPRIME: Comparative Effectiveness for Cooling Prospectively Infants With Mild Encephalopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nationwide Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's National Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Louis University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College Cork</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine effectiveness of therapy to improve neurodevelopmental outcomes in infants with&#xD;
      mild HIE. To determine the adverse effects of TH in mild HIE on the neonate and his/her&#xD;
      family. Determine heterogeneity of the treatment effect across key subgroups obtained in the&#xD;
      first 6 hours after birth prior to the decision to initiate therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study leverages practice variation within and across 15 participating sites to compare&#xD;
      the effectiveness of TH versus normothermia for mild HIE on neurodevelopmental outcomes at 2&#xD;
      years of age.After standardizing all aspects of clinical care for mild HIE (except for TH vs.&#xD;
      normothermia)we will enroll 460 infants with mild HIE into the longitudinal, observational&#xD;
      comparative effectiveness study.The central aim of the comparative longitudinal cohort of&#xD;
      mild HIE is (1) to compare the effectiveness of hypothermia to normothermia on&#xD;
      neurodevelopmental outcomes at 2 years, (2) determine the adverse effects of TH on the infant&#xD;
      and his/her family; and (3) determine the heterogeneity of treatment effects (moderating&#xD;
      effect) across mild HIE subgroups as determined by physiological biomarkers obtained during&#xD;
      the 6 hours window to initiate hypothermia. The decision to apply TH or normothermia will be&#xD;
      entirely determined by practice parameters at each site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Bayley IV</measure>
    <time_frame>22-26 months of age.</time_frame>
    <description>To compare the effectiveness of therapeutic hypothermia versus normothermia in each of the developmental domains (cognitive, language, motor) as a three dimensional vector.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MRI biomarkers</measure>
    <time_frame>4-5 days of age.</time_frame>
    <description>To determine the comparative effectiveness of TH based on the MRI injury score and the MRS measures of n-acetylaspartate and lactate.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Determine TH effect on prolonged length of stay.</measure>
    <time_frame>At time of discharge from hospital, up to 30 days from admission</time_frame>
    <description>Determine TH effect on prolonged length of stay as defined as &gt;7 day.</description>
  </other_outcome>
  <other_outcome>
    <measure>Determine TH effect on adverse events.</measure>
    <time_frame>At time of discharge from hospital, up to 30 days from admission</time_frame>
    <description>Determine adverse events from therapeutic hypothermia to include prolonged hospital stay shivering and possible exposure to narcotic/sedative agents bradycardia/cardiac arrhythmia, major vessel thrombosis or bleeding, thrombocytopenia and alteration of skin integrity.</description>
  </other_outcome>
  <other_outcome>
    <measure>Parental measures of bonding.</measure>
    <time_frame>4 months of age</time_frame>
    <description>Parent-infant Status will be assessed using a validated consisting of Mother-to-Infant Bonding Scale score &lt;2.</description>
  </other_outcome>
  <other_outcome>
    <measure>Parent measure of stress.</measure>
    <time_frame>4 months of age.</time_frame>
    <description>Baby Care Questionnaire eliciting parental perspectives on feeding, sleeping, and soothing infants in the home environment and is indicative of a parent's reliance on structure and attunement to child cues and test-retest coefficients &gt;0.81 associated with developmental outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Heterogeneity of the Total Sarnat Sore.</measure>
    <time_frame>Day of life 1</time_frame>
    <description>Determine the heterogeneity of the treatment effect across subgroups assessing TH responses as a function of Total Sarnat Score (≥ 5) in the first 6 hours of life in order to identify subgroups at high risk prior to the need to initiate cooling.</description>
  </other_outcome>
  <other_outcome>
    <measure>Heterogeneity of amplitude or continuous electroencephalography.</measure>
    <time_frame>Day of life 1</time_frame>
    <description>Determine the heterogeneity of the treatment effect across subgroups assessing the amplitude or continuous electroencephalography (abnormal background &lt;30microvolts or absence of sleep-wake cycles) in the first 6 hours in order to identify subgroups at high risk prior to the need to initiate cooling.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Mild Hypoxic Ischaemic Encephalopathy of Newborn</condition>
  <arm_group>
    <arm_group_label>Mild Hypoxic Ischemic Encephaolpathy</arm_group_label>
    <description>Infant ≥ 360/7 weeks with evidence of BOTH 1) perinatal event fetal acidosis and 2) encephalopathy on exam.&#xD;
Perinatal depression as defined by NICHD based on at least one of the following; pH &lt;7.00 in a cord gas or Base deficit ≥15 mmol/L in a gas (arterial or venous) obtained at &lt;60 min of age, Apgar score &lt;5 at 10 minutes, or Need for resuscitation at 10 minutes (i.e., chest compressions, or positive pressure respiratory support including endotracheal, mask ventilation, or CPAP).&#xD;
Mild encephalopathy, as defined by PRIME-study 1-6 hours after birth. At least 1 of 6 Sarnat criteria is scored as a mild, moderate, or severe abnormality, and Fewer than 3 of 6 Sarnat criteria are scored as a moderate or severe abnormality</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Normothermia</intervention_name>
    <description>Usual care for first 72 hours for neonates with mild encephaolpathy maintaining core temperature 36.0 - 37.0.</description>
    <arm_group_label>Mild Hypoxic Ischemic Encephaolpathy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Whole body therapeutic hypothermia</intervention_name>
    <description>Whole body therapeutic hypothermia (33.5°C + 0.5°C) for 72 hours begun by 6 hours of age, followed by rewarming at 0.5°C/hour for neonates with mild encephaolpathy per site standard of care practice.</description>
    <arm_group_label>Mild Hypoxic Ischemic Encephaolpathy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Term infants ≥ 36 weeks' gestation with evidence of both perinatal event fetal acidosis and&#xD;
        encephalopathy on exam.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infant ≥ 36 0/7 weeks with evidence of BOTH&#xD;
&#xD;
               1. Perinatal depression as defined by NICHD based on at least one of the following;&#xD;
                  pH &lt;7.00 in a cord gas or Base deficit ≥15 mmol/L in a gas (arterial or venous)&#xD;
                  obtained at &lt;60 min of age, Apgar score &lt;5 at 10 minutes, or Need for&#xD;
                  resuscitation at 10 minutes (i.e., chest compressions, or positive pressure&#xD;
                  respiratory support including endotracheal, mask ventilation, or CPAP).&#xD;
&#xD;
               2. Mild encephalopathy, as defined by PRIME-study 1-6 hours after birth:&#xD;
&#xD;
        At least 1 of 6 Sarnat criteria is scored as a mild, moderate, or severe abnormality, and&#xD;
        Fewer than 3 of 6 Sarnat criteria are scored as a moderate or severe abnormality&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Birthweight &lt;1800g (i.e., intrauterine growth restriction)&#xD;
&#xD;
          2. Head circumference &lt;30cm&#xD;
&#xD;
          3. Confirmed clinical or EEG seizures in the first 6 hours of life&#xD;
&#xD;
          4. Congenital malformation or genetic syndrome&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>36 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lina Chalak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lina Chalak, MD</last_name>
    <phone>214-648-3903</phone>
    <email>lina.chalak@utsouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pollieanna Sepulveda, BSN, RN</last_name>
    <phone>214-648-3698</phone>
    <email>pollieanna.sepulveda@utsouthwestern.edu</email>
  </overall_contact_backup>
  <reference>
    <citation>Prempunpong C, Chalak LF, Garfinkle J, Shah B, Kalra V, Rollins N, Boyle R, Nguyen KA, Mir I, Pappas A, Montaldo P, Thayyil S, Sánchez PJ, Shankaran S, Laptook AR, Sant'Anna G. Prospective research on infants with mild encephalopathy: the PRIME study. J Perinatol. 2018 Jan;38(1):80-85. doi: 10.1038/jp.2017.164. Epub 2017 Nov 2.</citation>
    <PMID>29095433</PMID>
  </reference>
  <reference>
    <citation>Chalak LF, Nguyen KA, Prempunpong C, Heyne R, Thayyil S, Shankaran S, Laptook AR, Rollins N, Pappas A, Koclas L, Shah B, Montaldo P, Techasaensiri B, Sánchez PJ, Sant'Anna G. Prospective research in infants with mild encephalopathy identified in the first six hours of life: neurodevelopmental outcomes at 18-22 months. Pediatr Res. 2018 Dec;84(6):861-868. doi: 10.1038/s41390-018-0174-x. Epub 2018 Sep 13.</citation>
    <PMID>30250303</PMID>
  </reference>
  <reference>
    <citation>Chalak LF, Adams-Huet B, Sant'Anna G. A Total Sarnat Score in Mild Hypoxic-ischemic Encephalopathy Can Detect Infants at Higher Risk of Disability. J Pediatr. 2019 Nov;214:217-221.e1. doi: 10.1016/j.jpeds.2019.06.026. Epub 2019 Jul 10. Erratum in: J Pediatr. 2020 Mar;218:e2.</citation>
    <PMID>31301853</PMID>
  </reference>
  <reference>
    <citation>El-Dib M, Inder TE, Chalak LF, Massaro AN, Thoresen M, Gunn AJ. Should therapeutic hypothermia be offered to babies with mild neonatal encephalopathy in the first 6 h after birth? Pediatr Res. 2019 Mar;85(4):442-448. doi: 10.1038/s41390-019-0291-1. Epub 2019 Jan 16.</citation>
    <PMID>30733613</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Lina Chalak</investigator_full_name>
    <investigator_title>PROFESSOR</investigator_title>
  </responsible_party>
  <keyword>mild HIE</keyword>
  <keyword>neonatal encephalopathy</keyword>
  <keyword>brain ischemia</keyword>
  <keyword>brain hypoxia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

